CPRX
CATALYST PHARMACEUTICALS, INC.
NASDAQ · Healthcare · Biotechnology · US
$31.49
+0.00%Oct 5, 2026, 03:15 UTC
Aurobindo Pharma received final USFDA approval to manufacture and market Perampanel tablets in multiple strengths in the US, with launch planned for Q3FY27.
Sep 29, 2026, 11:25 UTC
Aquestive Therapeutics, Inc. appointed Richard J. Daly as a director effective October 14, 2026, granting him 57,000 stock options under the company's 2018 Equity Incentive Plan.
Aug 14, 2026, 17:02 UTC
Chuck Royce reduced his fund's stake in Catalyst Pharmaceuticals during the second quarter of 2026, as disclosed in the 13F filing.
Source:Jul 16, 2026, 07:36 UTC
Angelini Pharma completed its acquisition of Catalyst Pharmaceuticals, gaining ownership of Catalyst's product portfolio and strengthening its presence in the U.S. market.
Source:Jul 10, 2026, 10:03 UTC
Catalyst Pharmaceuticals stockholders approved the merger with Angelini Pharma S.p.A. at a special meeting on July 8.
Source: